[1] Frere C, Debourdeau P, Hij A, et al. Therapy for cancer-related thromboembolism. Semin Onco. 2014;1(3):319–338.
[2] Ouriel K. Preventing complications of central venous catheterization. N Engl J Med. 2003; 348,2684–2686, 2684–2686.
[3] Geerts W. Central venous catheter-related thrombosis. Hematology Am Soc Hematol Educ Program. 2014; 2014(1):306–311.
[4] Wilimas J A, Hudson M, Rao B, et al. Late vascular occlusion of central lines in pediatric malignancies[J]. Pediatrics,1998,101(2):E7.
[5] Massicotte M P, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr. 1998;133(6):770–776.
[6] Sallah S, Wan J Y, Nguyen N P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87(4):575–579.
[7] Blom J W, Doggen C J, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA.2005;293(6):715–722.
[8] Chew H K, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464.
[9] Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients.[J]. Arch Pathol Lab Medicine. 2013;137(9):1286–1295.
[10] Streiff M B, Holmstrom B, Ashrani A, et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Nati Compr Canc Netw: JNCCN. 2015;13(9):1079–1095.
[11] Saber W, Moua T, Williams E C, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9(2):312–319.
[12] Debourdeau P, Chahmi D K, Zammit C, Farge-Bancel D. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. Pathol Biol (Paris).2008;56(4):211–219.
[13] Debourdeau P, Kassab C D, Le Gal G, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol. 2009;20(9):1459–1471.
[14] Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013;11(1):71–80.
[15] Hooke C. Recombinant tissue plasminogen activator for central venous access device occlusion. J Pediatr Oncol Nurs. 2000;17(3):174–178.
[16] Andris D A, Krzywda E A, Schulte W, Ausman R,Quebbeman EJ. Pinch-off syndrome: a rare etiology for central venous catheter occlusion. JPEN J Parenter Enteral Nutr.1994;18(6):531–533.
[17] Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21(19):3665–3675
[18] Kuhle S, Koloshuk B, Marzinotto V, et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res. 2003;111(4–5):227–233.
[19] Rosovsky R P, Kuter D J. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, andmanagement. Hematol Oncol Clin North Am. 2005;19(1):183–202.
[20] Boersma R S, Jie K G, Verbon A, van Pampus EC, Schouten HC. Thrombotic and infectious complications of central venous catheters in patientswith hematological malignancies. Ann Oncol. 2008; 19(3):433–442.
[21] Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venouscentral lines—a prospective study. Thromb Haemost. 1994;72(4):548–550.
[22] Frank D A, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD. The treatment and outcome of cancer patients with thromboses on central venouscatheters. J Thromb Thrombolysis. 2000;10(3):271–275.
[23] Khorana A A, Francis C W, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receivingoutpatient chemotherapy. J Thromb Haemost. 2007;5,632–634.
[24] Donnellan E, Kevane B, Bird B R H, Ainle FN. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol (Toronto, Ont.). 2014;21(3):134–143.
[25] Rong Y, Post D E, Pieper R O, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation byglioblastoma. Cancer Res. 2005;65(4):1406–1413.
[26] Regina S, Valentin JB, Lachot S, Lemarié E, Rollin J, Gruel Y. Increased tissue factor expression is associated with reduced survival innon-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem. 2009;55(10):1834–1842.
[27] NCCN Clinical Practice Guidelines in Cancer-Associated Venous Thromboembolic Disease (2019 Version I)[DB/OL]. http://www.nccn.org.
[28] Gerotziafas G T, Mahe I, Elalamy I. New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014;10:423–436.
[29] Prins M H, Lensing A W, Brighton T A, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials[J]. Lancet Haematol. 2014;1(1):e37-e46.
[30] Khorana A A, Vadhan-Raj S, Kuderer N M, et al. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial[J]. Thromb Haemost. 2017;117(11):2135–2145.
[31] Streiff M B, Holmstrom B, Angelini D, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289–1303.
[32] Lee J H, Hyun D G, Choi C M, et al. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancert al. Respiration; 2019:1–9.
[33] Saber W, Moua T, Williams E C, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: apatient-level data (IPD) meta-analysis of clinical trials and prospectivestudies. J Thromb Haemost. 2011;9(2):312–319.
[34] Wolberg A S, Aleman M M, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited. Anesth Analg. 2012;114(2):275–285.
[35] Watson T, Shantsila E, Lip G Y H. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet (London, England). 2009;373(9658):155–166.
[36] Elmoamly S, Mattar M, Yacoub M F, Afif A. Can Biomarkers of Coagulation, Platelet Activation, and Inflammation PredictVenous Thromboembolism in Patients with Haematological Malignancies? Acta Haematol. 2019;141(4):245–253.
[37] Mcgoldrick D M, Redmond H P. Venous thromboembolism prophylaxis risk assessment in a general surgery cohort: aclosed-loop audit. Ir J Med Sci. 2017;186(3):743–745.
[38] Baumann Kreuziger L, Jaffray J, Carrier M. Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. Thromb Res.2017;157:64–71.
[39] Parienti J, Mongardon N, Megarbane B, et al. Intravascular Complications of Central Venous Catheterization by Insertion Site. N Engl J Med. 2015;373(13):1220–1229.
[40] Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA. 2001;286(6):700–707.
[41] Zhong L, Wang H, Xu B, et al. Normal saline versus heparin for patency of central venous catheters in adultpatients - a systematic review and meta-analysis.[J]. Crit Care (London, England). 2017;21(1):5.
[42] Ingle R G, Agarwal A S. Pre-filled syringe - a ready-to-use drug delivery system: a review.[J]. Expert Opin Drug Deliv. 2014;11(9):1391–1399.